ArticleBlood cell therapy2026
Clinical Outcomes of Allogeneic Stem Cell Transplantation in Myelofibrosis - A Single Center Experience.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is paucity of data on the outcomes of allogeneic stem cell transplantation (allo-SCT) for myelofibrosis, from developing countries. Materials and Methods: This is a retrospective analysis of patients undergoing allogeneic stem cell transplant for myelofibrosis at our center between January 1998 to December 2023. Results: Thirty-four patients underwent allogeneic transplantation with a median age of 46 (19-68) years with 24 (70.6%) being males. The median dynamic international prognostic scoring system (DIPSS) Score was 3 (2-4). JAK2 was the most common driver mutation, in 10 (34.5%) patients. Majority of patients received reduced intensity conditioning with Fludarabine-Melphalan +/-total body irradiation (n=32) and all had peripheral blood grafts with donor source being matched sibling in 22 (64.7%), unrelated donor in 9 (26.5%) [7 full HLA match, one 9/10 HLA match and one 8/10 HLA match] and haploidentical in 3 (8.8%). The median CD34 cell dose infused was 9.9 (3.4-22) × 10 Conclusion: Allo-SCT for myelofibrosis is associated with reasonable cure rates, however strategies to reduce graft failure and GVHD are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.